Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Durvalumab + Tremelimumab
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Durvalumab Imfinzi MEDI4736 Immune Checkpoint Inhibitor 135 PD-L1/PD-1 antibody 79 Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, and in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer (FDA.gov).
Tremelimumab CP-675,206|Ticilimumab|CP-675206 CTLA4 Antibody 20 Immune Checkpoint Inhibitor 135 Tremelimumab (CP-675206) binds to and inhibits cytotoxic T-lymphocyte-associated protein 4 (CTLA4), thereby enhancing T-cell activation by blocking CTLA4-mediated inhibition of T-cell activation (PMID: 32620213, PMID: 32586937).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02716805 Phase I Durvalumab + Tremelimumab Phase 1 Study to Assess Safety & Tolerability of Tremelimumab & Durvalumab, Administered With High Dose Chemotherapy and Autologous Stem Cell Transplant Terminated USA 0
NCT02762006 Phase I Durvalumab + Tremelimumab Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma Completed USA 0
NCT03472274 Phase II Cisplatin + Doxorubicin + Methotrexate + Vinblastine Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Paclitaxel Durvalumab + Tremelimumab Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO) (DUTRENEO) Recruiting 1
NCT02542293 Phase III Cisplatin + Gemcitabine Carboplatin + Gemcitabine Durvalumab + Tremelimumab Carboplatin + Paclitaxel Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE). (NEPTUNE) Active, not recruiting USA 28
NCT03212469 Phase Ib/II Durvalumab + Tremelimumab A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer (ABIMMUNE) Recruiting 1
NCT03624231 Phase II Durvalumab Durvalumab + Tremelimumab Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC (DURTRE-RAD) Recruiting 1
NCT04625699 Phase II Durvalumab + Tremelimumab Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment Not yet recruiting USA 0
NCT02879318 Phase II Gemcitabine + Nab-paclitaxel Durvalumab + Tremelimumab Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Pancreatic Adenocarcinoma Active, not recruiting CAN 0
NCT03410615 Phase II Durvalumab + Tremelimumab Cisplatin Durvalumab Cisplatin Plus Radiotherapy vs Durvalumab Plus Radiotherapy Followed by Durvalumab vs Durvalumab Plus Radiotherapy Followed by Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Oropharyngeal SCC Recruiting CAN 3
NCT03206073 Phase Ib/II Durvalumab + Tremelimumab Durvalumab A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer Active, not recruiting USA 0
NCT04605731 Phase I Durvalumab + Tremelimumab Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer Recruiting USA 0
NCT03753919 Phase II Durvalumab + Tremelimumab Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (DUTHY) Recruiting 1
NCT02870920 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies Active, not recruiting CAN 0
NCT02549651 Phase I Durvalumab + Tremelimumab Durvalumab AZD9150 + Durvalumab MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Diffuse Large B-cell Lymphoma (D4190C00023) Completed USA 3
NCT02527434 Phase II Durvalumab + Tremelimumab Durvalumab Study of Tremelimumab in Patients With Advanced Solid Tumors Active, not recruiting USA 4
NCT02592551 Phase II Durvalumab + Tremelimumab Durvalumab MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma Active, not recruiting USA 0
NCT03237377 Phase II Durvalumab + Tremelimumab Durvalumab Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer Active, not recruiting USA | CAN 0
NCT03923270 Phase I Durvalumab + Tremelimumab Durvalumab Durvalumab + Olaparib Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer Recruiting USA 0
NCT02029001 Phase II Durvalumab + Tremelimumab Olaparib Pazopanib Nilotinib Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: My Own Specific Treatment (MOST plus) Recruiting 1
NCT03601455 Phase II Durvalumab + Tremelimumab Durvalumab Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer Active, not recruiting USA 0
NCT03122496 Phase I Durvalumab + Tremelimumab Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer Active, not recruiting USA 0
NCT04430452 Phase II Durvalumab Durvalumab + Tremelimumab Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for the Treatment of Liver Cancer After Progression on Prior PD-1 Inhibition Not yet recruiting USA 0
NCT03430895 Phase II Durvalumab + Tremelimumab Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract Completed USA 0
NCT03075527 Phase II Durvalumab + Tremelimumab A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma Suspended USA 0
NCT03150836 Phase II Durvalumab Durvalumab + Tremelimumab Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer Withdrawn USA 0
NCT03704480 Phase II Durvalumab + Tremelimumab Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy (IMMUNO-BIL) Recruiting 1
NCT02821754 Phase Ib/II Durvalumab + Tremelimumab A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) Recruiting USA 0
NCT03522584 Phase Ib/II Durvalumab + Tremelimumab Durvalumab, Tremelimumab and Stereotactic Body Radiation Therapy in Treating Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting USA 0
NCT03144778 Phase I Durvalumab Durvalumab + Tremelimumab Checkpoint Inhibitors Assessment in Oropharynx Carcinoma (CIAO) Completed USA 0
NCT02352948 Phase III Durvalumab Vinorelbine Durvalumab + Tremelimumab Gemcitabine Erlotinib Tremelimumab A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC) Active, not recruiting USA | CAN 24
NCT02879162 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours Active, not recruiting CAN 0
NCT02369874 Phase III Durvalumab + Tremelimumab Durvalumab Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer Completed USA 23
NCT02812420 Phase I Durvalumab + Tremelimumab Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Neoadjuvant Chemotherapy Active, not recruiting USA 0
NCT04073160 Phase I Durvalumab Durvalumab + Tremelimumab TRIO Bladder: A Phase Ib Study of Durvalumab (MEDI 4736) Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation, Based on Molecular Subtypes in Muscle-Invasive Bladder Cancer (TRIO Bladder) Withdrawn USA 0
NCT01975831 Phase I Durvalumab + Tremelimumab A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab Completed USA 0
NCT03026062 Phase II Tremelimumab Durvalumab + Tremelimumab Durvalumab Durvalumab and Tremelimumab in Combo Versus Sequential Recruiting USA 0
NCT03130764 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC Withdrawn 0
NCT02815995 Phase II Durvalumab + Tremelimumab Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes Active, not recruiting USA 0
NCT04397003 Phase II Carboplatin + Durvalumab + Etoposide Durvalumab + Tremelimumab Durvalumab + Personalized cancer vaccine + Tremelimumab Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) and Tremelimumab in Extensive Stage Small Cell Lung Cancer Not yet recruiting USA 0
NCT03802747 Phase I Durvalumab + Tremelimumab Durvalumab Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases Withdrawn 0
NCT03015129 Phase II Durvalumab Durvalumab + Tremelimumab A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer Active, not recruiting USA 0
NCT03911557 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors Recruiting USA 0
NCT03084471 Phase III Durvalumab + Tremelimumab Durvalumab An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. (STRONG) Active, not recruiting USA | CAN 6
NCT03158064 Phase II Durvalumab + Tremelimumab Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors Recruiting USA 0
NCT02938793 Phase II Durvalumab + Tremelimumab Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors Recruiting USA 0
NCT04522544 Phase II Durvalumab + Tremelimumab Durvalumab (MEDI4736) and Tremelimumab in Combination With Either Y-90 SIRT or TACE for Intermediate Stage HCC With Pick-the-winner Design Recruiting 1
NCT03057106 Phase II Cisplatin Gemcitabine Carboplatin Durvalumab + Tremelimumab Pemetrexed Disodium Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC Active, not recruiting CAN 1
NCT03373760 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer Active, not recruiting USA 0
NCT03298451 Phase III Sorafenib Durvalumab + Tremelimumab Durvalumab Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma Recruiting USA | CAN 15
NCT02154490 Phase II Docetaxel Nivolumab Palbociclib Durvalumab Ipilimumab + Nivolumab AZD4547 Taselisib Durvalumab + Tremelimumab Erlotinib + Rilotumumab Talazoparib Erlotinib Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Active, not recruiting USA | CAN 0
NCT03005002 Phase I Durvalumab + Tremelimumab Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver Completed USA 0
NCT03164616 Phase III Durvalumab + Tremelimumab Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Cisplatin + Gemcitabine Carboplatin + Gemcitabine Durvalumab Carboplatin + Nab-paclitaxel Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON) Recruiting USA 18
NCT02000947 Phase Ib/II Durvalumab + Tremelimumab A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer Completed USA 8
NCT02453282 Phase III Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Paclitaxel Tremelimumab Durvalumab + Tremelimumab Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC). (MYSTIC) Active, not recruiting USA | CAN 15
NCT03122509 Phase II Durvalumab + Tremelimumab A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer Completed USA 0
NCT03116529 Phase Ib/II Durvalumab + Tremelimumab Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma (NEXIS) Recruiting USA 0
NCT02794883 Phase II Tremelimumab Durvalumab + Tremelimumab Durvalumab Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma Unknown status USA 0
NCT03277482 Phase I Durvalumab + Tremelimumab Durvalumab Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer Recruiting USA 0
NCT03482102 Phase II Durvalumab + Tremelimumab Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer Recruiting USA 0
NCT02516241 Phase III Durvalumab + Tremelimumab Carboplatin + Cisplatin + Gemcitabine Durvalumab Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer Active, not recruiting USA | CAN 22
NCT02868632 Phase I Tremelimumab Durvalumab + Tremelimumab Durvalumab Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer Withdrawn USA 0
NCT03618134 Phase Ib/II Durvalumab Durvalumab + Tremelimumab Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner Recruiting USA 0
NCT03598816 Phase II Durvalumab + Tremelimumab PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma Withdrawn 0
NCT03837899 Phase Ib/II Durvalumab + Tremelimumab Durvalumab Durvalumab and Tremelimumab for Pediatric Malignancies Recruiting USA 6
NCT04817826 Phase II Durvalumab + Tremelimumab TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. (INFINITY) Recruiting 1
NCT03283605 Phase Ib/II Durvalumab + Tremelimumab Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas Recruiting CAN 0
NCT03452332 Phase I Durvalumab + Tremelimumab Stereotactic Ablative Radiotherapy (SABR) in Combination With Durvalumab and Tremelimumab in Patients With Cervical, Vaginal, or Vulvar Cancer Active, not recruiting USA 0
NCT02536794 Phase II Durvalumab + Tremelimumab MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer Completed USA 0
NCT04159974 Phase II Durvalumab Durvalumab + Tremelimumab RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus (RICE) Recruiting 1
NCT02639026 Phase I Durvalumab + Tremelimumab Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers Active, not recruiting USA 0
NCT02888743 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer Active, not recruiting USA | CAN 0
NCT03132467 Phase I Durvalumab + Tremelimumab Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer Active, not recruiting USA 0
NCT03275597 Phase I Durvalumab + Tremelimumab Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition Active, not recruiting USA 0
NCT02788773 Phase II Durvalumab + Tremelimumab Durvalumab Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer Active, not recruiting CAN 0
NCT03703297 Phase III Durvalumab Durvalumab + Tremelimumab Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Stage I-III Limited Disease Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC) Active, not recruiting USA | CAN 18
NCT03975114 Phase II Durvalumab + Tremelimumab Durvalumab A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5) (MILES-5) Recruiting 1
NCT04238637 Phase II Durvalumab Durvalumab + Tremelimumab Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) Recruiting 1
NCT03784066 Phase Ib/II Durvalumab + Tremelimumab Durvalumab Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity (DUTRELASCO) Recruiting 1
NCT02261220 Phase I Durvalumab + Tremelimumab A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors Completed USA | CAN 7
NCT03204812 Phase II Durvalumab + Tremelimumab Tremelimumab + Durvalumab Chemotherapy Naive CRPC Completed USA 0
NCT03529422 Phase I Durvalumab + Tremelimumab Durvalumab and Tremelimumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN Recruiting USA 0
NCT03638141 Phase II Durvalumab + Tremelimumab CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab Recruiting USA 0
NCT03101475 Phase II Durvalumab + Tremelimumab Synergism of Immunomodulation and Tumor Ablation (ILOC) Active, not recruiting 6


Additional content available in CKB BOOST